Volume 6.00 | Jan 9

Mammary Cell News 6.00 January 9, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Novel Noninvasive Therapy Prevents Breast Cancer Formation in Mice
A novel breast-cancer therapy partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, and it could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team reported. [Press release from the Wyss Institute of Biologically Inspired Engineering at Harvard University discussing online prepublication in Science Translational Medicine] Press Release | Abstract
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Sustained Activation of SMAD3/SMAD4 by FOXM1 Promotes TGF-ß-Dependent Cancer Metastasis
Scientists indicated that forkhead box M1 (FOXM1) promotes breast cancer metastasis by increasing nuclear retention of SMAD3 and identify crosstalk between FOXM1 and TGF-ß/SMAD3 pathways. [J Clin Invest]
Full Article

Human Breast Cancer Metastases to the Brain Display GABAergic Properties in the Neural Niche
Researchers found breast-to-brain metastatic tissue and cells displayed a GABAergic phenotype similar to that of neuronal cells. The GABAA receptor, GABA transporter, GABA transaminase, parvalbumin, and reelin were all highly expressed in breast cancer metastases to the brain. [Proc Natl Acad Sci USA] Abstract | Full Article

Pttg1/Securin Is Required for the Branching Morphogenesis of the Mammary Gland and Suppresses Mammary Tumorigenesis
PTTG1 is overexpressed in a number of human cancers and has been suggested to be an oncogene. However, researchers found that, in Pttg1-mutant females, the mammary epithelial cells showed increased proliferation and precocious branching morphogenesis. [Proc Natl Acad Sci USA] Abstract

The RNA-Binding Protein Musashi-1 Regulates Proteasome Subunit Expression in Breast Cancer- and Glioma-Initiating Cells
Researchers present evidence that the downregulation of the 26S proteasome in cancer stem cells constitutes another level of control by which Musashi-1 promotes signaling through the Notch pathway and maintenance of the stem cell phenotype of this subpopulation of cancer cells. [Stem Cells] Abstract

New Insights into Lineage Restriction of Mammary Gland Epithelium Using Parity-Identified Mammary Epithelial Cells
Researchers investigated the cellular identity and lineage potential of parity-identified mammary epithelial cells (PI-MECs) in intact mammary glands. After involution, PI-MECs are present exclusively in the luminal layer of mammary ducts. [Breast Cancer Res] Abstract | Full Article

Progesterone Stimulates Progenitor Cells in Normal Human Breast and Breast Cancer Cells
Scientists demonstrated that progesterone receptor is expressed in a subset of CD10+ basal cells and that progesterone stimulates this CD10+ cell compartment, which is enriched for bipotent progenitor activity. [Breast Cancer Res Treat] Abstract

Gold(III)-Dithiocarbamato Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia
Au(III) complexes were designed as carrier-mediated delivery systems exploiting peptide transporters which are up-regulated in some cancers. Among all, researchers focused on two compounds and tested them on human MDA-MB-231 breast cancer cell cultures and xenografts, discovering the proteasome as a major target both in vitro and in vivo. [PLoS One] Full Article

Exosomes Derived from Mesenchymal Stem Cells Suppress Angiogenesis by Down-Regulating VEGF Expression in Breast Cancer Cells
Exosomes from mesenchymal stem cells (MSCs) were isolated and characterized. MSC-derived exosomes exhibited different protein and RNA profiles compared with their donor cells and these vesicles could be internalized by breast cancer cells. [PLoS One] Full Article

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
Researchers report an epigenetic reprogramming pathway that is required for breast cancer metastasis. Analysis of human breast cancers revealed that this epigenetic program is significantly associated with poor clinical outcome. [Cell Rep] Full Article | Press Release | Graphical Abstract


A Phase II, Randomized, Multicenter Study Evaluating the Combination of Lapatinib and Vinorelbine in Women with ErbB2 Overexpressing Metastatic Breast Cancer
Investigators evaluated efficacy and safety of lapatinib plus vinorelbine, compared with lapatinib plus capecitabine, in women with human epidermal growth factor receptor 2-positive metastatic breast cancer. [Breast Cancer Res Treat] Full Article

Neoadjuvant Chemotherapy with Sequential Anthracycline-Docetaxel with Gemcitabine for Large Operable or Locally Advanced Breast Cancer: ANZ 0502 (NeoGem)
In metastatic breast cancer the combination of gemcitabine and a taxane has shown promising results. This Phase II study investigated the efficacy and safety of incorporating gemcitabine into neoadjuvant therapy. [Breast] Abstract

Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture - FREE Protocols
The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer – With What Drugs and for How Long?
The current debate is whether extended aromatase inhibitors or prolonged tamoxifen therapy should be given, and if so, to whom. The authors review some of the recent studies that have addressed this question and demonstrated further reduction in risk of recurrence, and discuss the clinical issues that face women and their health care providers in determining who should use which drug, and for how long. [Curr Oncol Rep] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Generex/Antigen Express Announce Database Lock of AE37 Breast Cancer Vaccine Trial
Generex Biotechnology Corporation announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. [Generex Biotechnology Corporation] Press Release

Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia and Genomic Health, Inc. [Specialised Therapeutics Australia Pty Ltd] Press Release

Ludwig Cancer Research Bestows Half a Billion in New Funding to Six Eminent U.S. Research Institutions
Cancer research in the U.S. got a critical boost as the six Ludwig Centers at Johns Hopkins University, Harvard University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University and the University of Chicago received a total of $540 million as part of a gift from Ludwig Cancer Research, on behalf of its founder, Daniel K. Ludwig. [Ludwig Institute for Cancer Research Ltd]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposia: Inflammation, Infection and Cancer
March 9-14, 2014
Whistler, Canada

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

NEW PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)

Postdoctoral Associate – Breast Cancer Development (University of Pittsburgh Cancer Institute)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us